DNA vaccines offer several potential advantages in development, manufacturing, re-dosing, safety and efficacy compared to conventional methods of vaccination. Foremost is the ability to elicit broad, antigen specific humoral and cellular immune responses without the potential safety issues associated with live pathogens. Despite these advantages, DNA vaccines tested in human clinical studies have not been able to induce immune responses of sufficient magnitude and consistency. This session will focus on strategies and technologies being used to effectively improve immunogenicity of DNA vaccines including improved delivery systems, antigen engineering and adjuvantation.

• Describe current breakthrough solutions for DNA vaccine discovery and development
• Present recent non-clinical and human clinical trial data with DNA vaccines using these technologies
• Discuss how to integrate these multiple technologies into functional platforms